PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
Tojyo Itaru, Shintani Yukari, Nakanishi Takashi, Okamoto Kenjiro, Hiraishi Yukihiro, Fujita Shigeyuki, Enaka Mayu, Sato Fuyuki, Muragaki Yasuteru,
¼Ò¼Ó »ó¼¼Á¤º¸
( Tojyo Itaru ) - Wakayama Medical University Department of Oral and Maxillofacial Surgery
( Shintani Yukari ) - Wakayama Medical University Department of Oral and Maxillofacial Surgery
( Nakanishi Takashi ) - Wakayama Medical University Department of Oral and Maxillofacial Surgery
( Okamoto Kenjiro ) - Wakayama Medical University Department of Oral and Maxillofacial Surgery
( Hiraishi Yukihiro ) - Japanese Red Cross Wakayama Medical Center Department of Dentistry and Oral Surgery
( Fujita Shigeyuki ) - Wakayama Medical University Department of Oral and Maxillofacial Surgery
( Enaka Mayu ) - Wakayama Medical University Department of Pathology
( Sato Fuyuki ) - Wakayama Medical University Department of Pathology
( Muragaki Yasuteru ) - Wakayama Medical University Department of Pathology
Abstract
Background: Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule that attenuates the immune response. PD-L1 contributes to failed antitumor immunity; thereby, blockade of PD-L1 with monoclonal antibody enhances the immune response. Recently, it was reported that PD-L1 was regulated by protein 53 (p53). Besides, cytokeratin 17 (CK17) is thought to be a diagnostic marker of oral squamous cell carcinoma (OSCC). Our aim was to evaluate the correlation between the immunohistochemical expression of PD-L1, p53 and CK17 with clinicopathological characteristics and disease-specific survival in patients with OSCC.
Methods: A total of 48 patients with OSCC were included in this study. Immunohistochemical staining was performed to evaluate the correlation among the expressions of PD-L1, p53 and CK17, and furthermore the correlation among various clinicopathological factors, PD-L1, p53 and CK17.
Results: The positive rate of p53, CK17, PD-L1 (tumor cells) and PD-L1 (tumor-infiltrating lymphocytes) was 63.2%, 91.7%, 48.9% and 57.1%. A statistically significant correlation between p53 expression and T stage and TNM stage (p = 0.049, p = 0.03, respectively) was observed. Also, a statistically significant correlation between p53 and PD-L1 (TCs) expression (p = 0.0009) was observed. Five-year disease-specific survival rate was not significantly correlated with gender, TNM stage, p53 expression, PD-L1 expression and CK17 expression.
Conclusion: The expression of p53 and PD-L1 shows significantly positive correlation in oral squamous cell carcinoma in tumor cells. Also, a significant correlation between p53 expression and T stage and TNM stage was observed. No other significant correlation between PD-L1 staining or CK17 and clinical or pathologic characteristics was identified.
Å°¿öµå
Oral squamous cell carcinoma (OSCC); Programmed death ligand 1 (PD-L1); Protein 53 (p53); Cytokeratin 17 (CK17); Immunohistochemistry; Disease-specific survival rate
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸